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        CD40, which is a member of the TNF receptor 
superfamily, is expressed on virtually all mature 
B lymphocytes and on most of their neoplastic 
counterparts. Upon interaction with CD40 ligand 
(CD40L), which is predominantly expressed on 
activated CD4  +   T cells, CD40 promotes B cell 
activation, proliferation, survival, and up-regu-
lation of surface molecules involved in antigen 
presentation (  1  ). The fi  nding that patients suf-
fering from   “  X-linked hyper-IgM syndrome  ”   
have a defect in expression of CD40L was in-
strumental in the discovery that CD40  –  CD40L 
interactions play a crucial role in T cell  –  depen-
dent (TD) immune response (  2, 3  ), contributing 
to germinal center (GC) formation, memory B cell 
development, Ig isotype switching, and affi   nity 
maturation (  4, 5  ). 
  The cytoplasmic tail of CD40, which lacks 
intrinsic catalytic activity, delivers signals to the 
cells by recruitment of TNF receptor  –  associated 
factors 1, 2, 3, 5, and 6. Interaction with its li-
gand leads to clustering of CD40 in lipid rafts and, 
fi  nally, to the recruitment of TNF receptor  – 
associated factor molecules (  6, 7  ). These events 
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  CD40, a member of the tumor necrosis factor (TNF) receptor family, plays an essential role 
in T cell  –  dependent immune responses. Because CD40 is widely expressed on the surface of 
tumor cells in various B cell malignancies, deregulated CD40 signaling has been suggested 
to contribute to lymphomagenesis. In this study, we show that B cell-specifi  c expression of 
a constitutively active CD40 receptor, in the form of a latent membrane protein 1 (LMP1)/
CD40 chimeric protein, promoted an increase in the number of follicular and marginal zone 
B cells in secondary lymphoid organs in transgenic mice. The B cells displayed an activated 
phenotype, prolonged survival and increased proliferation, but were signifi  cantly impaired 
in T cell-dependent immune responses. Constitutive CD40 signaling in B cells induced 
selective and constitutive activation of the noncanonical NF-    B pathway and the mitogen-
activated protein kinases Jnk and extracellular signal  –  regulated kinase. LMP1/CD40-
expressing mice older than 12 mo developed B cell lymphomas of mono- or oligoclonal 
origin at high incidence, thus showing that the interplay of the signaling pathways induced 
by constitutive CD40 signaling is suffi  cient to initiate a tumorigenic process, ultimately 
leading to the development of B cell lymphomas. 1318 CONSTITUTIVELY ACTIVE CD40 PROMOTES LYMPHOMAGENESIS | H  ö  mig-H  ö  lzel et al.
protein is able to deliver a ligand-independent constitutive 
CD40 signal by promoting self-aggregation in the plasma 
membrane (  23, 24  ). Constitutive CD40 signaling in B cells led 
to a strong accumulation of follicular and marginal zone B cells 
in secondary lymphoid organs, accompanied by a signifi  cant 
enlargement of follicles. These B cells displayed an activated 
phenotype, but failed to form GCs in response to immuniza-
tion with TD antigens. Ultimately, LMP1/CD40-expressing 
mice developed mono- or oligoclonal B cell lymphomas at 
high incidence, demonstrating that deregulated CD40 signal-
ing is suffi   cient to initiate B cell transformation. 
    RESULTS   
  Generation of transgenic mice expressing a conditional 
LMP1/CD40 transgene 
  To study constitutive CD40 signaling in vivo, mice expressing 
a fusion protein comprising the signaling domain of the hu-
man CD40 and the transmembrane domain of LMP1 (LMP1/
CD40) were generated. It had been shown earlier that human 
  CD40   can rescue the phenotype of   CD40  -defi  cient mice, in-
dicating that the receptors of both species are functionally 
equivalent (  25  ). A copy of the   LMP1/CD40   chimeric gene 
was inserted into the murine   rosa26   genomic locus of BALB/c-
derived embryonic stem (ES) cells by homologous recombi-
nation (  Fig. 1 A  ).   To restrict expression of   LMP1/CD40   in 
a cell type  –   and stage-specifi  c manner, we inserted a loxP-
fl  anked transcription and translation termination sequence (stop 
cassette) upstream of the   LMP1/CD40   coding sequence. 
After Cre-mediated excision of the stop-cassette, the   LMP1/
CD40   transgene is placed under the control of the ubiqui-
tously active   rosa26   promoter. Correctly targeted ES cell clones 
were identifi  ed by Southern blot analysis and used to establish 
the LMP1/CD40  fl  STOP   mouse strain. 
  The LMP1/CD40  fl  STOP   mice were crossed to CD19-Cre 
and CD21-Cre mice to activate expression of the chimeric pro-
tein from earlier (pro  –  /pre  –  ) or later (mature) stages of B cell 
development, respectively (  26, 27  ). Because off  spring of both 
crosses revealed the same immunological phenotype, results 
are presented for mice obtained from LMP1/CD40  fl  STOP  ;CD19-
Cre crosses only. In all biochemical experiments, only LMP1/
CD40  fl  STOP  ;CD19-Cre were analyzed. For simplicity, mice 
carrying one LMP1/CD40 knock-in allele and one CD19-
Cre allele will be referred to as LMP1/CD40 mice. As con-
trols, either LMP1/CD40  fl  STOP   or CD19-Cre mice were used. 
These control strains had an identical phenotype. In LMP1/
CD40 mice, deletion of the stop cassette could be detected in 
about half of BM and in almost all splenic B cells (  Fig. 1 B  ). 
This is consistent with previous reports showing a gradual in-
crease in Cre-mediated recombination in CD19-Cre mice as 
B cells proceed through their diff  erentiation (  27  ). Expression 
of the LMP1/CD40 protein in splenic cells after removal 
of the stop cassette was analyzed by Western blot analysis 
(  Fig. 1 C  ). LMP1/CD40 protein expression was detected 
in splenocytes isolated from LMP1/CD40 mice, but not 
in control mice (  Fig. 1 C  ), indicating that LMP1/CD40 is 
expressed after Cre-mediated   recombination and confi  rming 
initiate downstream signaling, resulting in activation of phospho-
inositide 3 kinase, phospholipase C    , mitogen-activated pro-
tein kinases (MAPKs), and NF-    B (  1, 6  ). Additionally, the 
Janus family kinase 3 (JAK3), which is associated with the cyto-
plasmic tail of CD40, undergoes phosphorylation, result-
ing in the activation of the signal transducer and activator of 
transcription 3 (  8  ). 
  The following three subfamilies of structurally related 
MAPKs are activated by CD40: extracellular signal-regulated 
kinase 1 (Erk1) and Erk2, the c-jun kinases Jnk1 and Jnk2, 
and the kinase p38/MAPK (  9  –  11  ). MAPKs are serine/threo-
nine protein kinases, which are activated by dual phosphory-
lation on a specifi  c tyrosine and threonine residue, respectively. 
After activation, MAPKs phosphorylate nuclear substrates 
such as the transcription factors c-Jun, Elk-1, Egr-1, and Atf-2, 
which in turn bind to specifi   c DNA sequences and thus 
modulate transcription (  1, 6  ). 
  CD40 signaling activates both the canonical and the non-
canonical NF-    B signaling pathways (  12, 13  ). In mammals, 
the NF-    B family consists of fi  ve genes coding for NF-    B1 
(p105/p50), NF-    B2 (p100/p52), RelA (p65), RelB, and 
c-Rel (  14  ). In unstimulated cells, the DNA-binding activity 
of NF-    B dimers is inhibited through the interaction with 
proteins of the inhibitor of the NF-    B (I    B) family. The ac-
tivation of the canonical NF-    B signaling pathway largely 
depends on ubiquitin-dependent degradation of small I    B 
proteins, leading to the nuclear translocation of NF-    B het-
erodimers p50/p65 and p50/c-Rel. The liberated heterodi-
mers are capable of binding DNA, and thereby activating 
gene expression. The noncanonical pathway depends on 
proteolytic cleavage of the precursor p100, liberating mainly 
p52/RelB heterodimers for nuclear translocation. Thus, ca-
nonical and noncanonical NF-    B signaling pathways induce 
the formation and nuclear translocation of distinct NF-    B 
heterodimers that activate distinct target genes (  15  –  17  ). 
  Whereas CD40 plays a decisive role in TD immune re-
sponses, aberrant CD40 signaling is suspected to play a critical 
role in the oncogenic processes of various cell types, includ-
ing B cells (  18  ). CD40 is widely expressed in B cell lymphomas 
and in selected carcinomas. Additionally, aberrant CD40L 
expression, which may lead to constitutive CD40 engagement, 
has been observed in several malignancies, including chronic 
lymphocytic leukemia, mantle cell lymphoma, follicular lym-
phoma, Burkitt  ’  s lymphoma, and breast cancer (  19  –  22  ). Thus, 
a contribution of this receptor to tumor pathogenesis has 
been suggested. 
  However, it is unclear whether aberrant CD40 signaling is 
suffi   cient to drive lymphomagenesis or whether it is only in-
volved in the maintenance of established malignancies. Ade-
quate experimental systems to explore this question are still 
missing. To study the biological and potential pathological ef-
fects of a constitutive CD40 activation, we generated knock-
in mice expressing in a conditional manner a chimeric protein 
consisting of the transmembrane domain of the Epstein-Barr 
viral latent membrane protein 1 (LMP1) and the intracellular 
signaling domain of CD40 (LMP1/CD40). This chimeric JEM VOL. 205, June 9, 2008 
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the tight control exerted by the stop cassette on transgene 
expression. To study whether the LMP1/CD40 fusion pro-
tein can substitute for CD40 in B cells, we tested its ability to 
promote Ig class switch recombination. We isolated splenic 
lymphocytes from LMP1/CD40 mice and stimulated them 
ex vivo with anti-CD40 agonistic antibody (    -CD40), IL-4, 
or     -CD40 plus IL-4. After 5 d, a distinct fraction of IgG1 
class-switched cells could be detected in cultures of LMP1/
CD40-expressing B cells upon stimulation with IL-4 only, 
whereas in the controls, IgG1  +   cells appeared only after co-
stimulation with     -CD40 and IL-4 (Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20080238/DC1). 
These data indicate that LMP1/CD40 induces Ig class switch 
recombination in the presence of IL-4, and thus constitutive 
CD40 signaling in murine B cells. 
  Increase of B and T cell numbers in LMP1/CD40 mice 
  Conditional expression of LMP1/CD40 in B cells resulted in 
a splenomegaly in 8  –  16-wk-old mice (  Fig. 2 A  ). The splenic 
weight of LMP1/CD40-expressing mice was, on average, 
increased by 3.5-fold compared with that of control mice 
(unpublished data). The splenomegaly was largely dependent 
on the increased number of B cells and, to a lesser degree, 
T cells. On average, eight times more B cells and three times 
more T cells were recovered from spleens of LMP1/CD40 mice 
compared with age-matched controls (  Fig. 2 B  ).   Immuno-
histochemical analysis of the spleen revealed that the overall 
follicular structure with the respective B and T cell zones, as 
well as the marginal zone, was retained (  Fig. 2 C  ). The size of 
the follicles, however, was signifi  cantly increased, with a larger 
expansion of the B cell compared with the T cell zone. 
  In LNs of LMP1/CD40 mice, absolute numbers of B 
cells were, on average, increased by fourfold compared with 
those of control mice, whereas absolute B cell numbers in the 
BM of mutant mice were unaff  ected (  Fig. 2 D  ). 
  LMP1/CD40-expressing B cells display an activated 
phenotype, but fail to form GCs 
  To determine the distribution of B cell subsets in LMP1/
CD40 mice, cells from BM, spleen, and inguinal LNs of 
experimental and control animals were stained for various 
surface markers and analyzed by fl  ow cytometry. In LMP1/
CD40 mice, the percentage of IgM  +  IgD  +   B cells was signifi  -
cantly increased in spleen and LN (  Fig. 3 A  ).   In the spleen, 
the percentage of marginal zone B cells was increased and 
numbers of CD21  +  CD23  +   follicular and CD21  high  CD23  low   
marginal zone B cells were, respectively, 8 and 12 times 
higher than those of controls (  Fig. 3, B and C  ). In the BM, 
the percentages of pro  –  , pre  –  , immature, and mature B cells 
were comparable in mutant and control mice (unpublished data). 
Flow cytometric analysis of the expression level of various 
activation and adhesion molecules revealed an increase in 
surface expression of CD95, ICAM-1, MHC class II, CD80, 
and CD86 in B cells isolated from the spleen and LN of 
LMP1/CD40 mice (  Fig. 3 D   and not depicted), suggesting an 
activated phenotype. To test whether LMP1/CD40-  expressing 
    Figure 1.     Generation of transgenic mice conditionally expressing 
LMP1/CD40.   (A) Targeting strategy for the insertion of a conditional 
  LMP1/CD40   allele   (LMP1/CD40  fl  STOP )   into the murine   rosa26 -locus.  Cre-
mediated recombination leads to deletion of the stop cassette and ex-
pression of   LMP1/CD40   under transcriptional control of the endogenous 
  rosa26  -promoter. The scheme of the targeting construct shows the EcoRI 
recognition sites and the location of the probe. The expected fragments 
after EcoRI digestion and hybridization with the labeled probe are indi-
cated by the thin lines. SAS, splice acceptor site; STOP, Stop cassette, XbaI, 
site of insertion. (B) Southern blot analysis of EcoRI-digested genomic 
DNA showing the deletion effi  ciency of the stop cassette in B cells of the 
spleen (SP; lane 3) and the BM (lane 6) of LMP1/CD40 mice. DNA from B 
cells of control mice (lanes 2 and 5) and mice heterozygous for   LMP1/
CD40  fl  STOP    (lane 1 and 4) was included. B cells were purifi  ed by using mag-
netic beads against CD19. After deletion of the stop cassette, the rosa26 
probe detects a 5.2-kb fragment (LMP1/CD40). The 15- and 7.1-kb frag-
ments represent the wild-type   rosa26   allele  ( rosa26   locus) and the tar-
geted allele (  LMP1/CD40  fl  STOP   ), respectively. The deletion effi  ciency was 
    50% in the BM and almost complete in the spleen. (C) LMP1/CD40 pro-
tein expression. Western blots were prepared from spleen lysates of 
LMP1/CD40;CD19-Cre (lanes 1 and 2) and control mice (lane 3). As con-
trol, protein lysates of 293 cells transiently transfected with a LMP1/CD40 
expression vector were included in the analysis (lane 4). The 56-kD LMP1/
CD40 chimeric protein was detected by an anti  –  human CD40 antibody. 
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subsets (Fig. S3, available at http://www.jem.org/cgi/content/
full/jem.20080238/DC1). These data indicate that both B 
and T cells were activated in LMP1/CD40 mice. 
  LMP1/CD40-expressing B cells proliferate spontaneously 
and have a prolonged survival in vitro 
  To determine the survival properties of LMP1/CD40-ex-
pressing and control B cells, we cultured such cells for 5 d in 
the presence or absence of     -CD40. The cells were stained 
daily with the vital dye TOPRO-3, and then subjected to 
fl  ow cytometric analysis (  Fig. 4 A  ).   The percentage of living 
cells dropped dramatically in control culture in the absence 
of CD40 stimulation, whereas the same culture conditions 
only modestly aff  ected the viability of LMP1/CD40-ex-
pressing cells. Furthermore, absolute numbers of living cells 
were determined for LMP1/CD40-expressing cells and con-
trols over time (  Fig. 4 B  ). An increase in the number of 
B cells could participate in TD immune responses, we immu-
nized mice with the hapten (3-hydroxy 4-nitrophenylacetyl 
[NP]) conjugated to the carrier chicken gammaglobulin. 
In contrast to control mice, the fraction of GC B cells was 
drastically reduced in the spleens of LMP1/CD40 mice, 
and GC structures could not be detected by immunohisto-
chemistry, suggesting that constitutive CD40 signaling im-
pairs the recruitment and/or maintenance of B cells within 
GCs (Fig. S2, available at http://www.jem.org/cgi/content/
full/jem.20080238/DC1). 
  As expected, T cells showed no deletion of the stop cas-
sette, as analyzed by PCR (unpublished data), but were ex-
panded and showed an activated phenotype in LMP1/CD40 
mice. The ratio between CD4 and CD8 cells was comparable 
to the controls (unpublished data), but staining for CD44 and 
CD62L expression revealed a shift from naive toward acti-
vated and memory-type T cells among the CD4 and CD8 
    Figure 2.     B cell  –  specifi  c LMP1/CD40 expression results in an increase in B and T cell numbers in secondary lymphoid organs.   (A)  LMP1/
CD40 mice showed a splenomegaly with a 3.5-fold increase of the splenic weight compared with control mice with B cells carrying the stop 
cassette (LMP1/CD40  fl  STOP  ). Representative spleens from 8-wk-old LMP1/CD40 and control mice are shown. (B) Absolute numbers of B220  +   B  cells 
and CD3  +   T cells in spleen (SP) of LMP1/CD40 and control mice. The horizontal bars mark the mean. (C) Spleen sections from LMP1/CD40 and control 
mice were stained for B cells (red, anti-IgM) and T cells (top; blue, anti-CD3), or for B cells (red, anti-IgM) and metallophilic macrophages (blue, 
anti-MOMA1), which are localized at the border between follicular (FO) and marginal zone (MZ) B cells (bottom). Arrowheads indicate marginal 
zone B cells. Bars, 400   μ  m. (D) Absolute numbers of B220  +   B cells in inguinal LN and BM of LMP1/CD40 and control mice. The horizontal bars mark 
the mean.     JEM VOL. 205, June 9, 2008 
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compared with control cells. In contrast, no signifi  cant change 
in the level of phosphorylated p38/MAPK could be detected 
in untreated transgenic B cells (  Fig. 5, A and B  ).   Upon cross-
linking of the endogenous CD40 receptor, the activation of 
the MAPKs was further increased in LMP1/CD40-positive 
cells, although to a lower extent compared with control cells 
(  Fig. 5 B  ). To evaluate whether improved survival of LMP1/
CD40-expressing B cells requires activation of the MAPK 
pathways, we cultured LMP1/CD40-expressing and control 
B cells in the presence of the Mek1/2 inhibitor U0126 and 
the Jnk inhibitor SP600125, preventing the phosphorylation 
of Erk and the kinase activity of Jnk, respectively (  28, 29  ). 
The Mek1/2 inhibitor abrogated the improved survival of 
ex vivo  –  isolated LMP1/CD40-expressing B cells, whereas 
the Jnk inhibitor had a less dramatic eff  ect (  Fig. 5 C  ). These 
data suggest that the enhanced survival mediated by LMP1/
CD40 is more dependent on Erk than Jnk activity. 
  Because CD40-induced B cell proliferation and survival 
critically depend on the activation of NF-    B (  22  ), the canon-
ical and noncanonical NF-    B signaling pathways were ana-
lyzed in LMP1/CD40-expressing B cells. In gel retardation 
assays, both unstimulated LMP1/CD40-expressing and con-
trol B cells exhibited similar amounts of p50/p65 complexes 
LMP1/CD40-expressing cells was observed even without 
additional stimulation, indicating not only better survival but 
also spontaneous cell division. Additionally, B cells of LMP1/
CD40 mice and controls were labeled with CFSE, cultured 
with or without     -CD40, IL-4,     -CD40 plus IL-4, or LPS, 
followed by fl  ow cytometric analysis after 5 d (  Fig. 4 C  ). 
Compared with control cells, a higher percentage of LMP1/
CD40-expressing cells proliferated in the absence of exoge-
nous stimuli or after stimulation with IL-4. Triggering of 
CD40 resulted in increased proliferation of control B cells, 
which could be further increased by the addition of IL-4, 
whereas proliferation of LMP1/CD40-expressing cells was 
not increased upon CD40 cross-linking. Proliferation upon 
LPS stimulation was comparable in both cell types. 
  B cell  –  specifi  c expression of LMP1/CD40 activates the 
MAPKs Jnk and Erk and the noncanonical NF-    B pathway 
  Because it has been shown that cross-linking of the CD40 re-
ceptor induces activation of the MAPKs Erk, Jnk, and p38/
MAPK (  1, 6  ), the phosphorylation status of these proteins 
was tested by Western blot analysis. The phosphorylated 
forms of Jnk and Erk were increased by approximately four- 
to sixfold in unstimulated LMP1/CD40-expressing B cells 
    Figure 3.     B cell  –  specifi  c expression of LMP1/CD40 results in an increase and activation of B cells.   (A) Lymphocytes of spleen (SP) and inguinal 
LNs were analyzed for the expression of IgM and IgD by fl  ow cytometry. Numbers indicate the mean percentages and SD of gated populations. SP: fol-
licular (FO) B cells (IgM  + IgD +  ), marginal zone (MZ), and transitional B cells (IgM  + IgD low  ); LN: IgM  + IgD +  . Values were calculated from seven independent 
experiments. (B) Flow cytometric analysis of follicular B cells (FO; CD21  int CD23 +  ) and marginal zone B cells (MZ; CD21  high CD23 low  ) in the spleen. Numbers 
indicate mean percentages and standard deviations of B220  +   B cells displaying a MZ B or FO B cell phenotype. Values were calculated from seven inde-
pendent experiments. (C) Absolute numbers of FO and MZ B cells in the spleens of LMP1/CD40 and control mice. (D) Splenocytes were stained with anti-
bodies specifi  c for the indicated activation and adhesion markers. Histograms show surface expression of the indicated markers on gated B220  +   B  cells 
from LMP1/CD40 (continuous line) and control (dotted line) mice. Lymphocytes isolated from LNs showed a similar extent of activation (not depicted).     1322 CONSTITUTIVELY ACTIVE CD40 PROMOTES LYMPHOMAGENESIS | H  ö  mig-H  ö  lzel et al.
assays (  Fig. 6 A  ). Furthermore, in Western blots, increased 
p52 protein levels could be detected in mutant B cells com-
pared with control B cells, whereas p100 levels were compa-
rable (  Fig. 6 B  ), thus indicating constitutive activation of the 
noncanonical NF-    B signaling pathway. 
  To corroborate these fi  ndings, we analyzed the protein 
levels of NF-    B components in the cytoplasm and nucleus. 
In accordance with the previous results, the levels of RelB 
and p52 were elevated, whereas p65 and c-Rel levels were 
similar in nuclear fractions of LMP1/CD40 and control cells 
(  Fig. 6 C  ). However, c-Rel levels were signifi  cantly  de-
creased in the cytoplasm of LMP1/CD40-expressing B cells. 
Additionally, a signifi  cant increase in p50 levels was found in 
nuclear extracts of LMP1/CD40-expressing cells, which is 
most likely caused by the increased p105 levels found in the 
cytoplasm. The increased p50 level might lead to the forma-
tion of p50/p50 homodimers, lacking a transactivation domain. 
It has been shown that, in tumor cells, p50/p50 homodimers 
interact with Bcl3, resulting in transcriptional activation of 
NF-    B target genes. This is mostly correlated with elevated 
Bcl3 levels. However, in LMP1/CD40-expressing cells we 
could detect neither increased levels of p50/p50 homodimer 
formation in gel retardation assays (Fig. S4 A) nor elevated 
Bcl3 levels in the nuclear fraction (  Fig. 6 C  ), suggesting that 
most p50 is bound to RelB and thereby   contributes to the 
(  Fig. 6 A   and Fig. S4 A, available at http://www.jem.org/
cgi/content/full/jem.20080238/DC1).   Stimulation of the 
endogenous CD40 receptor resulted in a robust induction of 
DNA-binding p50/p65 complexes in control cells. This ex-
tent of induction could be seen in neither unstimulated nor in 
    -CD40  –  stimulated LMP1/CD40-expressing B cells (  Fig. 6 A   
and Fig. S4 A). These data indicate that the canonical NF-    B 
signaling pathway is not constitutively activated in LMP1/
CD40-expressing cells. The data were confi  rmed by Western 
blot analysis showing that I    B-     levels were comparable in 
control and LMP1/CD40-expressing B cells, and that I    B-     
was not constitutively phosphorylated in unstimulated LMP1/
CD40 B cells. As shown in   Fig. 6 B,   I    B-     was even less 
phosphorylated in unstimulated LMP1/CD40-expressing cells 
than in control B cells. Inhibition of de novo I    B-     synthesis 
by addition of cycloheximide excluded the possibility that 
pI    B-     cannot be detected in the Western blots because of an 
increased high turnover rate of I    B in unstimulated LMP1/
CD40-expressing B cells (Fig. S4 B). Upon CD40 stimula-
tion, degradation of I    B-     in B cells expressing LMP1/CD40 
was delayed in comparison to control cells, indicating that in 
mutant cells the canonical NF-    B signaling pathway can be 
activated, but to a lower extent than in control cells (Fig. S4 B). 
In contrast to control cells, we could detect a RelB-contain-
ing complex in LMP/CD40-positive B cells in gel retardation 
    Figure 4.     LMP1/CD40 expression triggers survival and spontaneous proliferation of primary B cells in vitro.   Splenic B cells of LMP1/CD40 and 
control mice were enriched by depletion of CD43  +   cells. Cells were cultured for up to 5 d with anti-CD40 antibody (    -CD40) or without stimulation (w/o). 
(A) Percentages of living cells (Topro negative) were determined daily by fl  ow cytometry. The bars show mean percentages of living cells of three indepen-
dent experiments. Error bars show the SD. (B) Numbers of viable cells were determined daily by trypan blue staining and cell counting. The bars show 
mean cell counts of three independent experiments. Error bars show the SD. (C) Splenic B cells of LMP1/CD40 and control mice were labeled with CFSE 
and cultured with     -CD40, IL-4,     -CD40 plus IL-4, LPS, or without stimulation (w/o). After 5 d of culture, the proliferation rate of B220  +   B cells was de-
termined by fl  ow cytometric analysis of the CFSE staining. Percentages of divided cells   ±   the SD of three individual experiments are indicated.   JEM VOL. 205, June 9, 2008 
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centage of LMP1/CD40-expressing mice older than 12 mo 
showed obvious signs of disease. Those mice were further ana-
lyzed and showed an extreme splenomegaly with a 20  –  40-
fold increase in weight, signifi  cantly enlarged inguinal LNs, 
hepatomegaly, and nodular infi  ltrates in the kidney, lung, and 
liver (Fig. S5, available at http://www.jem.org/cgi/content/
full/jem.20080238/DC1). 
  To confi  rm lymphoma development in these mice, splenic 
cells were analyzed for mono- or oligoclonality by Southern 
blot analysis using a probe spanning the J  H  3-4 region of the 
mouse IgH locus. In contrast to the controls, all spleen cell 
activity of the noncanonical NF-    B signaling pathway. Col-
lectively, these results indicate that constitutive activation of 
CD40 favors the activation of the noncanonical NF-    B sig-
naling pathway. 
  LMP1/CD40 mice develop B cell lymphomas 
  Because LMP1/CD40-expressing B cells exhibited sponta-
neous proliferation and enhanced survival in vitro, which 
might ultimately lead to the development of malignancies, 
we monitored the mice for the occurrence of B cell lym-
phomas by regularly palpating the abdomen. A high per-
    Figure 5.     LMP1/CD40 expression induces activity of the Jnk- and Erk-signaling pathways.   (A) Whole-cell extracts of splenic B cells of LMP1/
CD40 (L/C) and control (co) mice from three independent preparations (1  –  3) were loaded on one gel and analyzed for Jnk (Jnk2, 54 kD; Jnk1, 46 kD), Erk 
(Erk1. 44kD; Erk2, 42 kD), p38/MAPK (38 kD) and the corresponding phosphorylated forms with specifi  c antibodies. Equal protein loading was controlled 
by Ponceau S staining. The graph shows the mean values of the fold induction of the signals from the unphosphorylated and phosphorylated forms of 
Jnk, Erk, and p38/MAPK compared with the signals in control cells. Mean values and SDs were calculated from at least fi  ve independent experiments. SDs 
are shown by error bars. *, P   <   0.05; **, P   <   0.001, calculated by the two-tailed Student  ’  s   t   test. (B) After CD40 triggering, LMP1/CD40-expressing cells are 
damped in activation compared with control cells. Splenic B cells of LMP1/CD40 and control mice were stimulated with     -CD40 antibody for the indi-
cated time points, and Western blots were performed as described in A. Equal protein loading was controlled by tubulin staining. One representative ex-
periment out of three is shown. (C) The improved survival of LMP1/CD40-expressing B cells is dependent on continuous Erk phosphorylation. Splenic B 
cells of LMP1/CD40 and control mice (CD19-Cre) were cultured for up to 5 d with the Mek1/2 inhibitor U0126 (dotted line) and the Jnk-inhibitor 
SP600125 (dashed line; triangle and square, respectively). As control, B cells from LMP1/CD40 and control mice were cultured in the presence of DMSO 
(continuous lines, rectangle, and circle, respectively). Percentages of living cells (Topro negative) were determined by fl  ow cytometry at day 1, 3, and 5. 
The bars show mean percentages of living cells of three independent experiments. Error bars show the SD.     1324 CONSTITUTIVELY ACTIVE CD40 PROMOTES LYMPHOMAGENESIS | H  ö  mig-H  ö  lzel et al.
samples of diseased LMP1/CD40 mice showed beside the 
germline IgH band one or more distinct additional bands, 
indicating a mono- or oligoclonal outgrowth of B cells (  Fig. 
7 A  ).   This was further confi  rmed by the sequence analysis 
of the CDR3 region (Fig. S6, available at http://www.jem
.org/cgi/content/full/jem.20080238/DC1). Whereas several 
rearrangements could be amplifi  ed in wild-type cells, only 
one or two rearrangements were amplifi  ed from the tumor 
samples. None of the lymphomas carried IgH somatic mu-
tations. The tumors were further characterized by immuno-
histopathology and FACS analysis. Hematoxylin and eosin 
(HE) staining of spleen sections showed a nodular infi  ltrate 
characterized by the presence of small and large lymphoid 
cells that could not be seen in the controls (  Fig. 7 B  ). Nine 
tumors were further analyzed by immunohistochemical 
stainings. Staining for B220 and CD3 surface markers dem-
onstrated that in seven cases, the expanded population was 
    Figure 6.     LMP1/CD40 expression induces activity of the nonca-
nonical NF-    B pathway  . (A) Splenic B cells of LMP1/CD40 and control 
(co) mice were cultured with (+) or without (   )     -CD40 for 1 h. Nuclear 
extracts were incubated with radioactively labeled DNA oligonucleotides 
containing a NF-    B binding site and separated by gel electrophoresis. For 
supershift experiments, the indicated antibodies were added to the ex-
tracts. (B) Whole-cell extracts of splenic B cells of LMP1/CD40 and control 
(CD19-Cre) mice from three independent preparations (1  –  3) were loaded 
on one gel and analyzed by immunoblot. The expression levels of p100 
and p52 as well as of I   B    and  pI  B    are shown. Equal protein loading 
was verifi  ed by Ponceau S staining. (C) Cytoplasmic (CP) and nuclear (N) 
levels of NF-    B components of splenic B cells from LMP1/CD40 and con-
trol (CD19-Cre) mice were analyzed by immunoblot. Purity of cytoplasmic 
and nuclear extracts was verifi  ed by     -tubulin and     -Bcl3 staining, re-
spectively. Equal protein loading was controlled by Ponceau S staining. 
The experiment was performed three times.     
    Figure 7.     LMP1/CD40 mice develop mono- and oligoclonal lym-
phomas.   (A) Southern blot analysis to examine IgH gene confi  guration 
with an IgH-specifi  c probe. Genomic DNA was prepared and digested 
with EcoRI from splenic cells of LMP1/CD40 mice that developed neopla-
sias (34, 142, 176, 197, 230, 247, 365, and 221), one young LMP1/CD40 
mouse (900; 3 mo of age), as well as a control mouse (905). The sequence 
analysis of the amplifi  ed IgH genes is shown in Fig. S6. (B) Representative 
histological analyses of diseased LMP1/CD40 mice and age matched con-
trol mice. (1) HE-stained normal spleen. (2) HE-stained spleen representa-
tive for diseased LMP1/CD40 mice, showing prominent nodular tumor 
infi  ltrates. (3) Lymphoma infi  ltrate within the spleen of a representative 
diseased LMP1/CD40 mouse. B cells were visualized by immunohisto-
chemistry using an antibody specifi  c for B220. (4) Higher magnifi  cation 
of section described in 3. (5) Dispersed reactive T cells within the lym-
phoma infi  ltrate were detected by an anti-CD3  –  specifi  c antibody. 
A representative highly magnifi  ed section is shown. Bars: (1 and 2) 400 
  μ  m; (3) 100   μ  m; (4, 5, and inset) 25   μ  m. (C) Flow cytometric analysis of 
splenic cells for the expression of IgM and IgD. The gates were set ac-
cording to the age-matched controls. For the diseased LMP1/CD40 mice, 
a shift toward one or two main populations could be observed, as shown 
for three representative samples. Fig. S6 is available at http://www.jem
.org/cgi/content/full/jem.20080238/DC1.   JEM VOL. 205, June 9, 2008 
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  Scoring lymphoma development by immunohistopatho-
logical and molecular analyses revealed that approximately 
60% (11/19) of LMP1/CD40 mice between the age of 12 
and 19 mo developed lymphomas, whereas the frequency of 
lymphoma development in the control population was   <  10% 
(1/14;   Fig. 8  ).   These data show that deregulated CD40 ex-
pression in B cells leads to a high incidence of lymphoma de-
velopment in mice. 
    DISCUSSION   
  Deregulated CD40 signaling has been described in several 
human malignancies (  18  ). Yet, the question of whether ab-
errant CD40 signaling is suffi   cient to promote tumorigenesis 
remains unresolved. To investigate biological and pathologi-
cal roles of constitutive CD40 signaling in B cells, we used 
the transmembrane domain of LMP1 as a surrogate to in-
duce ligand-independent aggregation of the CD40 intracel-
lular signaling domain. We show that constitutive CD40 
signaling in B cells leads to a signifi  cant increase in peripheral 
mature B cells and, ultimately, to the development of mature 
B cell lymphomas. 
  Previous in vitro experiments have shown that the 
LMP1/CD40 fusion protein acts similar to LMP1 in terms of 
self-aggregation and is able to mimic ligand-triggered CD40 
signaling with respect to the activation of NF-    B and stress-
activated protein kinases (  23, 24  ). In this study, we show that 
B cell  –  specifi  c LMP1/CD40 expression in transgenic mice 
can replace CD40  –  CD40L interaction to promote immuno-
globulin class switching, thus indicating that LMP1/CD40 
indeed acts as a constitutively active CD40 receptor. B cell  –
  specifi  c expression of LMP1/CD40 in mice caused spleno-
megaly with an accumulation of both follicular and marginal 
zone B cells. The expansion of transgenic B cells may depend 
on their prolonged survival and/or increased proliferation as 
demonstrated by our ex vivo studies and in vivo BrdU incor-
poration assays (  Fig. 6   and unpublished data). Despite their 
activated status, transgenic B cells were strongly impaired in 
GC formation. This is in accordance with a previous study 
showing that LMP1/CD40 is able to down-regulate   bcl6  , 
which is a key regulator of the GC reaction (  30  ). We ob-
served not only an accumulation of B cells but also of acti-
vated CD4  +   and CD8  +   T cells in young LMP1/CD40 mice. 
It is unlikely that this T cell expansion is caused by a leakiness 
of Cre recombinase expression because the same T cell ex-
pansion was observed in crossings with two independent 
B cell  –  specifi  c Cre lines (CD19-Cre and CD21-Cre). Addi-
tionally, deletion of the stop cassette in T cells of LMP1/
CD40 mice could not be detected by PCR (unpublished 
data). Therefore, the observed T cell expansion might instead 
be caused by an antigen-independent bystander eff  ect induced 
by LMP1/CD40-expressing B cells. It has been shown that 
production of cytokines, as well as cell surface molecules, ex-
pressed on antigen-presenting cells during an immune response 
can activate T cells nonspecifi  cally (  31, 32  ), and that CD40-acti-
vated antigen-presenting cells promote the expansion of memory 
T cells (  33, 34  ), suggesting that LMP1/CD40-expressing 
composed of B220  +  CD3        B cells (  Fig. 7 B  ). In two B220        
cases, B cell derivation of the expanded cell population could 
be confi  rmed by staining for the B cell markers Pax5/BSAP 
and CD79a (unpublished data). Within the expanded B cell 
population, small CD3  +   T lymphocytes could be detected 
(  Fig. 7 B  ). 
  Further analysis of the B cell populations in spleen, LN, 
peritoneal cavity, and BM by FACS analysis revealed an ab-
errant B cell population in most cases, which was either 
IgM  +  IgD        or IgM  low  IgD  +  , and a strong reduction of the nor-
mal IgM  +  IgD  high   population (  Fig. 7 C  ). In one case, we ob-
served a selective outgrowth of CD4  +   T cells. The B cell 
lymphomas were heterogenous in the expression of CD95, 
but all showed a strong down-regulation of CD21 and CD23 
(Fig. S7 A, available at http://www.jem.org/cgi/content/full/
jem.20080238/DC1). None of the tumor cells tested showed 
a signifi  cant up-regulation of LMP1/CD40 expression com-
pared with premalignant cells (Fig. S7 B). 
  To determine the activity of NF-    B and MAPK in tu-
mor cells, we performed Western blot analysis. We could de-
tect elevated p52 levels in three out of seven tumor samples 
tested. (Fig. S8, A and B, available at http://www.jem.org/
cgi/content/full/jem.20080238/DC1). In three out of seven 
tumor samples, pI    B-     levels were increased compared with 
premalignant LMP1/CD40-expressing cells. Approximately 
25% (2/7) and 90% (6/7) of tumor samples displayed consti-
tutive Jnk and Erk phosphorylation, respectively. These data 
indicate that distinct signaling pathways are activated in the 
various tumor samples, suggesting that diff  erent secondary 
events drive B cell transformation (Fig. S8, A and B). 
    Figure 8.     LMP1/CD40 mice develop lymphomas with a high inci-
dence.   Kaplan-Meier curve for lymphoma incidence in LMP1/CD40 and 
control mice. Lymphomas were scored by histopathology and by investi-
gating mono-/oligoclonality, using Southern blot analysis and/ or PCR 
amplifi  cation of the immunoglobulin genes, followed by sequence analy-
sis. Reduction of the control group between 50 and 80 wk is caused by 
the analysis of these mice. At each time point, a diseased LMP1/CD40 
mouse was analyzed, an age-matched control mouse was included. Drop-
outs that were caused by nonlymphoma-derived death were equal in both 
groups. In the age between 12 and 19 mo, 11/19 LMP1/CD40-mice and 
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even less active in the mutant cells than in unstimulated con-
trol B cells. Additionally, in comparison to control B cells, 
p105 levels were increased, whereas c-Rel levels were de-
creased, in the cytoplasm of LMP1/CD40-expressing B cells. 
Whether this alteration is caused by the constitutive activa-
tion of CD40 or a direct consequence of the constitutively 
activated noncanonical NF-    B pathway remains to be deter-
mined. The question arises why LMP1/CD40 expression in 
B cells leads selectively to the activation of the noncanonical 
NF-    B pathway. In wild-type B cells, CD40 ligation results 
in a fast and robust activation of the canonical NF-    B activity, 
which is rapidly counteracted by multiple negative-feedback 
mechanisms, whereas the noncanonical NF-    B pathway re-
sponds more slowly and appears to lack strong negative-feed-
back mechanisms (  39  ). This might explain the preferential 
chronic activation of the noncanonical NF-    B pathway in 
LMP1/CD40-expressing B cells. Recently, two studies have 
provided compelling evidence that the noncanonical NF-    B 
pathway plays a critical role in multiple myeloma (MM) patho-
genesis (  40, 41  ). Thus, 20% of patients with MM were found 
to carry mutations in essential NF-    B components, leading 
mainly to the activation of the noncanonical NF-    B pathway 
(  41  ). Of note, in some cases of MM, a strong up-regulation of 
CD40 was observed. As shown for CD30 (  42  ), CD40 over-
expression might lead to self-aggregation of CD40, resulting 
in ligand-independent constitutive CD40 signaling, and thus 
creating a primary oncogenic event similar to that seen in our 
experimental system. 
  In addition to the noncanonical NF-    B pathway, the 
MAPKs Erk and Jnk were constitutively phosphorylated in 
unstimulated LMP1/CD40-expressing B cells. The impor-
tance of Erk phosphorylation for the improved survival of ex 
vivo  –  isolated LMP1/CD40-expressing B cells was supported 
by the fact that the survival advantage by LMP1/CD40 ex-
pression was abrogated in the presence of the Mek1/2 inhibi-
tor UO126. The Ras  –  Raf  –  Mek  –  Erk pathway has been 
implicated in malignant transformation of various cell types 
and has been associated with proliferation and survival of he-
matopoietic cells (  43  ). A basal constitutive activity of Erk, 
which has been attributed to CD40, CD30, and RANK sig-
naling, has also been described in the Hodgkin-Reed Stern-
berg tumor cells of Hodgkin disease (  44  ). Treatment of 
Hodgkin disease cell lines with the MEK inhibitor UO126 
resulted in the inhibition of proliferation, underlining the 
importance of constitutive Erk phosphorylation for the pro-
liferation of Hodgkin lymphoma cell lines. Unlike premalig-
nant LMP1/CD40 B cells, constitutive Erk phosphorylation 
was not consistently detected in all independent primary tu-
mors derived from LMP1/CD40-expressing B cells. This re-
sult suggests the existence of distinct oncogenic partners 
involved in CD40-driven lymphomagenesis, some of which 
may bypass the need for Erk activation. 
  Our results provide direct evidence that constitutive 
CD40 signaling leads to the selective activation of the nonca-
nonical NF-    B pathway and the MAPKs Jnk and Erk. The 
concerted action of these signaling pathways ultimately leads 
B cells may be able to generate an activating environment 
for T cells. 
  Deregulated CD40 signaling induced the development of 
lymphomas in   >  60% of mice older than 1 yr. Consistent with 
the B cell  –  specifi  c expression of LMP1/CD40 and the eff  ects 
of constitutive CD40 signaling on B cell survival and prolif-
eration, most of these tumors were of clonal B cell origin. 
Only 1 out of 11 lymphomas was T cell derived. In all other 
tumors, the expanded population carried clonal IgH rear-
rangements and expressed B cell markers. The nodular growth 
pattern of the lymphomas was reminiscent of follicular lym-
phomas (  35  ). However, in contrast to follicular lymphomas, 
the variable regions of the immunoglobulin genes cloned from 
LMP1/CD40-expressing B lymphoma cells were unmutated, 
indicating a pre-GC origin. The late onset of tumor develop-
ment, the heterogeneity in surface marker expression, and the 
activity of distinct signaling pathways suggest that multiple 
  independent secondary oncogenic hits cooperate with CD40 
activation to promote lymphomagenesis. 
  A role for CD40 signaling in the pathogenesis of human 
B cell lymphomas and carcinomas has previously been sug-
gested. We provide strong evidence that constitutive CD40 
signaling exerts transforming activity in vivo. The oncogenic 
property of constitutive CD40 signaling appears in contrast 
with the previously reported therapeutic eff   ects of CD40 
triggering in hematopoietic malignancies (  18, 36  ). Indeed, 
triggering the CD40 receptor can promote growth arrest and 
cell death of malignant CD40-expressing cells and can induce 
an autologous antitumor T cell response by up-regulating the 
costimulatory molecules B7.1 and B7.2 (  37  ). Our data sug-
gest that this therapeutic approach might not be risk free. The 
level and duration of the CD40 signal may critically infl  uence 
the balance between the apparently contrasting biological ef-
fects triggered by CD40 signaling. Indeed, low-level consti-
tutive engagement of CD40 was shown to induce proliferation 
of lymphoma cells, whereas treatment of malignant cells with 
high doses of agonistic anti-CD40 antibodies or CD40L re-
sulted in cell cycle arrest and apoptosis (  20  ). 
  Our gel retardation and nuclear fractionation experiments 
revealed that, compared to control B cells, RelB-contain-
ing complexes are increased in the nuclei of LMP1/CD40-
expressing B cells, indicating constitutive activation of the 
noncanonical NF-    B pathway. We suggest that in LMP1/
CD40-expressing B cells, RelB dimerizes with either p50 or 
p52, which were both found to be increased in the nuclear 
fraction. This is in accordance with previous reports showing 
that the noncanonical NF-    B pathway based on p100 pro-
cessing leads to the nuclear translocation of not only RelB/
p52 but also of RelB/p50 dimers (  17, 38  ). In contrast to 
the noncanonical pathway, the canonical NF-    B pathway 
was not found to be activated in LMP1/CD40-expressing 
B cells, as indicated by similar p65 and c-Rel levels in the 
nuclear fractions of unstimulated LMP1/CD40-expressing B 
cells and control B cells. The reduced basal phosphorylation 
of I    B-     in LMP1/CD40-expressing B cells compared with 
control B cells suggests that the canonical NF-    B pathway is JEM VOL. 205, June 9, 2008 
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CFSE (fi  nal concentration 5   μ  M; Invitrogen) for 10 min at 37  °  C. CFSE-la-
beled cells were cultured for up to 5 d in 96-well plates (5   ×   10  5  /well) in B 
cell medium and analyzed by fl  ow cytometry. For treatment with small 
chemical inhibitors, B cells were cultured with 2.5   μ  M SP600125 (Ag Sci-
entifi  c), 10   μ  M UO126 (Cell Signaling Technology), or DMSO (Calbio-
chem) in B cell medium for up to 5 d. 
  For Western blots and gel retardation assays, B cells were purifi  ed from 
spleen, using magnetic beads against CD43 (MACS; Miltenyi Biotec), and 
stimulated from 5 min for up to 24 h with agonistic anti-CD40 anti-
bodies (10   μ  g/ml; J Bioscience [HM40-3]). For I    B-     degradation assays, 
B cells were treated with 10   μ  M cycloheximide (Sigma-Aldrich) 30 min 
before stimulation. 
  Tumor cells.     Primary tumor cells were frozen in RPMI, 10% DMSO, and 
20% FCS. Because all tumor cells are CD43  +  , we were not able to purify 
them with magnetic beads as we did for premalignant cells. Therefore, after 
thawing, cells were cultured for 2 d to obtain a purer tumor cell population 
before Western blots extracts were prepared. 
  Flow cytometry.     Single-cell suspensions prepared from various lymphoid 
organs were surface stained with combinations of FITC, PE, Cy-Chrome 
(Cyc), APC, and Cy5.5-conjugated monoclonal antibodies. Antibodies to 
B220, CD4, CD5, CD8, CD21, CD23, CD43, CD44, CD80, CD95, IgD, 
IgG1, and IgM were purchased from BD Biosciences and the antibody to 
CD62L was purchased from Immunotech. Additional monoclonal anti-
bodies to CD54 and CD86 were provided by J. Mysliwietz (Helmholtz 
Center, Munich, Germany). Peanut agglutinin  –  FITC was purchased from 
Vector Laboratories. All analyses were made with a FACSCalibur (BD Bio-
sciences) and results were analyzed using CellQuest software. Data were ana-
lyzed from 3   ×   10  4   viable lymphocyte-gated cells as determined by forward 
and side scatter and propidium iodide or Topro-3 (Invitrogen) staining. 
  Immunohistochemistry.     Spleens were embedded in OCT Tissue-Tek 
(Sakura), frozen on dry ice, and cut into 8-  μ  m-thick sections. The sections 
were thawed, air dried, fi  xed in acetone, and incubated for 30 min at 22  °  C 
in a humidifi  ed chamber with anti-biotin, anti-avidin solution (Avidin/Bio-
tin blocking kit; Vector Laboratories). 
  Sections were stained using peroxidase-conjugated anti  –  mouse IgM 
(Sigma-Aldrich), rat anti  –  mouse CD3 (provided by E. Kremmer, Helmholtz 
Center, Munich, Germany), and rat anti  –  mouse MOMA-1 (T-2011; BMA) 
antibodies. Biotin-conjugated mouse anti  –  rat IgG1 (Jackson ImmunoRe-
search Laboratories) was used to detect MOMA-1 or CD3 antibodies, and 
streptavidin coupled to alkaline phosphatase (Sigma-Aldrich) to detect the 
biotin-conjugated mouse anti  –  rat IgG1 antibody. Streptavidin-coupled anti-
bodies were detected by the reaction with an alkaline phosphate substrate kit 
(Vector Laboratories), and peroxidase-coupled antibodies were detected by 
the reaction with 3-amino-9-ethylcarbazole (peroxidase substrate kit; Vector 
Laboratories). All incubation steps were performed at 22  °  C in humidifi  ed 
chamber, followed by three washing steps with PBS. Slides were analyzed 
with a microscope (Carl Zeiss, Inc.); pictures were obtained with a digital 
camera (RS Photometrics) and processed with Openlab (Improvision) and 
Photoshop (Adobe) software. Immunohistochemical staining of paraffi   n sec-
tions was performed on an automated immunostainer (Ventana Medical Sys-
tems) according to the manufacturer  ’  s protocols. Antigen retrieval was 
performed with a microwave pressure cooker in 0.01 M citrate buff  er (pH 
6.0). Incubation with the primary antibodies was performed overnight at 
room temperature. The rest of the procedure was completed on the Ventana 
immunostainer. The antibodies used included B220 (BD Biosciences), CD3 
(Dako), Pax5 (BD Biosciences), and CD79a (clone HM57; Dako). Positive 
controls for all the antibodies investigated were used to confi  rm the adequacy 
of the staining. 
  Electrophoretic mobility shift assay.     Nuclear protein extracts were pre-
pared from stimulated and unstimulated cells, as previously described (  47  ). The 
electrophoretic mobility shift assay was performed with a NF-    B  –  specifi  c 
to B cell lymphomagenesis. The mouse model described in 
this paper provides a tool to dissect the contribution of these 
signaling pathways to lymphomagenesis in vivo. 
    MATERIALS AND METHODS   
  Generation of the transgenic mouse line LMP1/CD40.     The   LMP1/
CD40   chimeric gene was isolated from the plasmid p1778.16 encoding aa 
1  –  190 from LMP1 fused to aa 223  –  280 of human CD40 (  23  ). The adenine 
at position 243 bp after the ATG of the LMP1 gene was replaced by a cyto-
sine, introducing a silent mutation, to destroy a potential splice acceptor side. 
To insert the   LMP1/CD40   fusion gene into the   rosa26  -locus, the vector 
pRosa26-1 was used (  45  ). Before introducing   LMP1/CD40  , pRosa26-1 
was modifi  ed by introducing a loxP-fl  anked region, consisting of a stop cas-
sette containing a transcription and translation termination site (  46  ), the gene 
encoding the red fl  uorescent protein (not expressed in this context), and a 
neomycin-resistance gene fl  anked by frt sites. The   LMP1/CD40   fusion gene 
was cloned downstream of the stop cassette. The fi  nal targeting vector was 
electroporated into BALB/c-derived ES cells. The targeted ES cells were 
screened for homologous recombination by Southern blot analysis. The 
DNA was digested with EcoRI and hybridized with a specifi  c   rosa26   probe 
(  45  ). Recombinant ES cells were injected into C57BL/6 blastocysts, which 
were then transferred into foster mothers to obtain chimeric mice. 
  Mice.     Mice carrying the   LMP1/CD40  fl  STOP     allele were crossed either to 
the CD19-Cre or the CD21-Cre mouse strain (on a C57BL/6 background) 
to generate mice expressing the transgene in early B cell stages in the 
BM ([LMP1/CD40  fl  STOP  ;CD19-Cre] F1) or in mature B cells ([LMP1/
CD40  fl  STOP  ;CD21-Cre] F1), respectively. Off  spring were routinely screened 
by PCR using primer specifi  c for   LMP1/CD40   (5    LMP1, 5    -AGGAGCC-
CTCCTTGTCCTCTA-3    ; 3    CD40, 5    -CTGAGATGCGACTCTCTTT-
GCCAT-3    ) and   CD19-Cre   or   CD21-Cre   (  26, 27  ). 
  Only mice of the F1 generation were used in this study and analyzed at 
8  –  16 wk of age unless stated otherwise. As controls, LMP1/CD40  fl  STOP   and 
CD19-Cre  –   or CD21-Cre  –  expressing mice were used. All mice were bred 
and maintained in specifi  c pathogen-free conditions, and the experiments 
were performed in compliance with the German animal welfare law and 
have been approved by the institutional committee on animal experimenta-
tion and the government of Upper Bavaria. 
  Western blot.     3   ×   10  6   cells were lysed in Laemmli buff  er or NP40 lysis 
buff  er, and lysates were separated on a SDS-PAGE gel and transferred to a 
nitrocellulose or PVDF membrane. LMP1/CD40 protein was detected by 
the anti  –  human CD40 antibody (sc975), which was like anti  –  I    B-     (sc-
371), purchased from Santa Cruz Biotechnology, Inc. MAPKs and their 
phosphorylated forms were detected by anti-p38/MAPK, anti  –  phospho-
p38/MAPK (pT180/pY182), anti-Erk (p44/42), anti  –  phospho-Erk (pT202/
pY204), anti-Jnk (56G8), and anti  –  phospho-Jnk (pT183/pY185), all pur-
chased from Cell Signaling Technology. The phosphorylated form of I    B-     
was detected by anti  –  phospho-I    B-     (Cell Signaling Technology). Signals 
were visualized with ECL Western Blotting Detection Reagents (GE 
Healthcare). The amount of loaded protein was standardized against tubulin 
using an anti-tubulin antibody (Dianova). After scanning of the fi  lms with an 
Expression 1680Pro scanner (Epson), quantifi  cation of bands was performed 
with the TINA software package (Raytest). Protein expression values of con-
trol mice were set to 1 to achieve comparability between diff  erent Western 
blots. P values were determined by applying the two-tailed Student  ’  s   t   test. 
  In vitro cultures.     Splenic cells were cultured for up to 5 d in 96-well plates 
(5   ×   10  5   cells/well). Stimuli included lipopolysaccharide (20   μ  g/ml;   Esche-
richia coli   055:B5; Sigma-Aldrich), IL-4 (10 ng/ml; mouse recombinant; 
Sigma-Aldrich), and anti-CD40 antibody (10   μ  g/ml; BD Biosciences; 3/23). 
Cells were stained and analyzed with a FACSCalibur or counted using try-
pan blue to exclude dead cells. For proliferation assays, splenic cells (5   ×   10  6   
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